Evidence map›Paper›PMID 35548793›Full record

ArticleRSC advances2018

Biophysical evaluation to categorize pathogenicity of cancer-predisposing mutations identified in the BARD1 BRCT domain.

Rajan Kumar Choudhary, M Quadir Siddiqui, Nikhil Gadewal, Nachimuthu Senthil Kumar, Ekaterina S Kuligina, Ashok K Varma

Open access · goldAbstract read
In one paragraph

Article in RSC advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. BARD1: A Friend or Foe in Pancreatic Ductal Adenocarcinoma?International journal of molecular sciences · 2025
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 4 countries.

Rajan Kumar ChoudharyAdvanced Centre for Treatment, Research and Education in Cancer Kharghar Navi Mumbai Maharashtra 410 210 India avarma@actrec.gov.in +91-22-2740 5085 +91-22-2740 5112.
M Quadir SiddiquiAdvanced Centre for Treatment, Research and Education in Cancer Kharghar Navi Mumbai Maharashtra 410 210 India avarma@actrec.gov.in +91-22-2740 5085 +91-22-2740 5112.
Nikhil GadewalAdvanced Centre for Treatment, Research and Education in Cancer Kharghar Navi Mumbai Maharashtra 410 210 India avarma@actrec.gov.in +91-22-2740 5085 +91-22-2740 5112.
Nachimuthu Senthil KumarDepartment of Biotechnology, Mizoram University (A Central University) Aizawl - 796 004 Mizoram India.
Ekaterina S KuliginaLaboratory of Molecular Oncology, Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology RU-197758, Pesochny-2 St.-Petersburg Russia.
Ashok K VarmaAdvanced Centre for Treatment, Research and Education in Cancer Kharghar Navi Mumbai Maharashtra 410 210 India avarma@actrec.gov.in +91-22-2740 5085 +91-22-2740 5112.ORCID https://orcid.org/0000-0001-6091-5315
Advanced Centre for Treatment, Research and Education in Cancer · INHebrew University of Jerusalem · ILHomi Bhabha National Institute · INInstitute of Oncology NN Petrov · RUMizoram University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The BRCT domain of BARD1 (BARD1 BRCT) is involved in many cellular processes such as DNA damage repair (DDR) and cell-cycle checkpoint regulation. BARD1 BRCT performs tumor suppressor function by recruiting BRCA1 at DNA damage site

Identifiers

PMID35548793
PMCPMC9086705
OpenAlexW2895600205

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.